In NSCLC, particularly adenocarcinoma, TTF-1 expression has long been associated with favorable prognosis and enhanced sensitivity to pemetrexed-based chemotherapy [10,11]. This evidence concerns the gene TTF1 and non-small cell lung carcinoma.